Fig. 7.

Differences in MIR200 methylation between carcinoma and sarcoma. (A) Hypomethylation of promoters of MIR200A-MIR200B-MIR429 and hypermethylation of enhancers annotated by chromHMM state of MIR200C-MIR141 between two cancer types. Methylation scores of different uterine cancers are displayed. The chromHMM tracks of nine ENCODE cell lines (H1 ESC, GM12878, K562, HepG2, HUVEC, HMEC, HSMM, NHEK, and NHL) are displayed. (B) Differential expression of MIR200 family in different cancer types using TCGA expression data. (C and D) Proposed model for methylation-induced aberrant expression changes of MIR200 family and downstream pathway. EC represents endometrial cancers of grade 1, 2, or 3. UCSs may be either homologous or heterologous. Homologous UCSs are those whose sarcomatous component is nonspecific or corresponds to normal uterine tissue types such as an ESS or leiomyosarcoma. Heterologous UCSs are those containing an element of a specific nonuterine sarcoma such as rhabdomyosarcoma, chondrosarcoma, or osteosarcoma.